Traws Pharma, Inc.
TRAW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001130598
No open-market purchases or sales by Traws Pharma, Inc. insiders were filed in the last 90 days; 34 institutions reported holding it in 13F filings for Q2 2026, worth $5.19M in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Traws Pharma, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- +7 vs. Q3 2024
- Shares held
- 1.17M
- +524.0K (+81.1%) vs. Q3 2024
- Total value
- $10.2M
- +$6.45M (+169.7%) vs. Q3 2024
- New holders
- 9
- 3 more added
- Sold out
- 2
- 2 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TRAW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 34 | $5.19M |
| Q1 2026 | 28 | $6.62M |
| Q4 2025 | 22 | $3.86M |
| Q3 2025 | 18 | $2.41M |
| Q2 2025 | 19 | $1.87M |
| Q1 2025 | 19 | $3.98M |
| Q4 2024 | 19 | $10.2M |
| Q3 2024 | 12 | $3.80M |
| Q2 2024 | 30 | $1.36M |
| Q1 2024 | 26 | $1.88M |
| Q4 2023 | 27 | $1.35M |
| Q3 2023 | 28 | $1.27M |
| Q2 2023 | 24 | $2.19M |
| Q1 2023 | 25 | $1.04M |
| Q4 2022 | 29 | $1.01M |
| Q3 2022 | 30 | $1.54M |
| Q2 2022 | 32 | $2.36M |
| Q1 2022 | 28 | $3.60M |
| Q4 2021 | 34 | $6.14M |
| Q3 2021 | 37 | $10.5M |
| Q2 2021 | 24 | $10.9M |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Traws Pharma, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 605,531 | $5.38M | 0.11% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 164,157 | $1.46M | 0.04% | +164,157 | New |
| Alyeska Investment Group, L.P. | 116,714 | $1.04M | 0.00% | +116,714 | New |
| Ikarian Capital, LLC | 98,493 | $874.6K | 0.25% | +98,493 | New |
| Vestal Point Capital, LP | 75,000 | $666.0K | 0.04% | +75,000 | New |
| Geode Capital Management, LLC | 20,801 | $184.7K | 0.00% | +20,801 | New |
| Morgan Stanley | 15,725 | $139.6K | 0.00% | +14,996+2,057.1% | Added |
| Vanguard Group Inc | 13,141 | $116.7K | 0.00% | −13,581−50.8% | Reduced |
| Boothbay Fund Management, LLC | 28,431 | $108.2K | 0.00% | +28,431 | New |
| Renaissance Technologies LLC | 10,052 | $89.3K | 0.00% | +10,052 | New |
| Millennium Management LLC | 10,012 | $88.9K | 0.00% | +10,012 | New |
| BlackRock, Inc. | 9,956 | $88.4K | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 1,164 | $10.3K | 0.00% | +1,100+1,718.8% | Added |
| UBS Group AG | 791 | $7.02K | 0.00% | +161+25.6% | Added |
| Vermillion & White Wealth Management Group, LLC | 205 | $1.82K | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 155 | $1.38K | 0.00% | +155 | New |
| Bank of America Corp | 76 | $675 | 0.00% | −2,062−96.4% | Reduced |
| Pacific Capital Wealth Advisors, Inc | 2 | $18 | 0.00% | 00.0% | Unchanged |
| Cornerstone Planning Group LLC | 1 | $7 | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −379−100.0% | Sold out |
| Danske Bank A/S | 0 | $0 | 0.00% | −7−100.0% | Sold out |